Cargando…
Modified nusinersen intrathecal injection method: inclusion of a septal needle-free closed infusion connector
OBJECTIVE: Nusinersen, an extremely expensive biologic drug (around 100,000 US$ per dose) that needs to be administered intrathecally, is approved for the treatment of 5q-spinal muscular atrophy (SMA). Because of the low muscle tone of the back muscles of pediatric SMA patients, especially type 1 SM...
Autores principales: | Zhang, Yani, Zheng, Kelu, Liang, Cuili, Zheng, Ruidan, Chen, Jinghui, Jiang, Minyan, Zhou, Zhizi, Zhao, Yuan, Rao, Min, Yang, Sida, Chen, Wenxiong, Liu, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551161/ https://www.ncbi.nlm.nih.gov/pubmed/37808480 http://dx.doi.org/10.3389/fneur.2023.1234442 |
Ejemplares similares
-
Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
por: Haché, Manon, et al.
Publicado: (2016) -
Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
por: Stolte, Benjamin, et al.
Publicado: (2018) -
Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy
por: Orbach, Rotem, et al.
Publicado: (2022) -
Intrathecal nusinersen administration in adult spinal muscular
atrophy patients with complex spinal anatomy
por: Cordts, Isabell, et al.
Publicado: (2020) -
Intrathecal administration of nusinersen for spinal muscular atrophy: report of three cases with severe spinal deformity
por: Nakao, Sayo, et al.
Publicado: (2020)